R
Richard Kay
Researcher at Novartis
Publications - 32
Citations - 1191
Richard Kay is an academic researcher from Novartis. The author has contributed to research in topics: Asthma & Regression analysis. The author has an hindex of 18, co-authored 32 publications receiving 1070 citations. Previous affiliations of Richard Kay include University of Sheffield & John Radcliffe Hospital.
Papers
More filters
Journal ArticleDOI
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
Sherif Gonem,Rachid Berair,Amisha Singapuri,Ruth Hartley,Marie Laurencin,Gerald Bacher,Björn Holzhauer,Michelle Bourne,Vijay Mistry,Ian D. Pavord,Adel H. Mansur,Andrew J. Wardlaw,Salman Siddiqui,Richard Kay,Christopher E. Brightling +14 more
TL;DR: Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with persistent moderate-to-severe asthma and raised sputum eOSinophil counts despite inhaled corticosteroid treatment.
Journal ArticleDOI
Transformations of the explanatory variables in the logistic regression model for binary data
Richard Kay,Sarah Little +1 more
TL;DR: This article improved the fit of the logistic regression model for binary data by transforming the vector of explanatory variables, which are the functions of the explanatory variables which appear in the log density ratio of the conditional distributions.
Journal ArticleDOI
Quality control during the conventional analysis of semen, an essential exercise.
TL;DR: Although in general the intra-technician variability was low, there were marked and clinically significant differences between observers when assessing the same semen sample, and Technicians should be recruited who have natural ability as observers.
Journal ArticleDOI
Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids.
Eric D. Bateman,Alfredo Guerreros,Florian Brockhaus,Björn Holzhauer,Abhijit Pethe,Richard Kay,Robert G. Townley +6 more
TL;DR: Fevipiprant appears to be efficacious and well-tolerated in this patient population, with an optimum total daily dose of 150 mg, and further investigations into the clinical role of fevipipant in suitably designed phase III clinical trials are warranted.
Journal ArticleDOI
Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: A single-center study.
Ruth Hartley,Bethan Barker,Chris Newby,Mini Pakkal,Simonetta Baldi,Radhika Kajekar,Richard Kay,Marie Laurencin,Richard P. Marshall,Ana R. Sousa,Harsukh Parmar,Salman Siddiqui,Sunil Gupta,Christopher E. Brightling +13 more
TL;DR: In asthmatic patients and patients with COPD, lung function impairment is strongly associated with air trapping, with a contribution from proximal airway narrowing in asthika patients.